Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | RAB9A | P51151 | 6/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | PKM | P14618 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | PLIN1 | O60240 | 3/20 | 0.61 |
| ▸ | PLIN5 | Q00G26 | 3/20 | 0.61 |
| ▸ | ABHD5 | Q8WTS1 | 3/20 | 0.61 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.61 |
| ▸ | RECQL | P46063 | 2/20 | 0.61 |
| ▸ | BCHE | P06276 | 1/20 | 0.61 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | KRAS | P01116 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4400320 | 1.00 | MAPT (1.00) | MAPTRAB9ANPC1PKMLMNA | |
| SCHEMBL12257967 | 0.95 | MAPT (0.90) | MAPTRAB9ANPC1PKMLMNA | |
| SCHEMBL1929871 | 0.90 | PKM (0.82) | MAPTRAB9ANPC1PKMLMNA | |
| SCHEMBL1929873 | 0.90 | PKM (0.82) | MAPTRAB9ANPC1PKMLMNA | |
| SCHEMBL9221198 | 0.90 | NPC1 (0.81) | MAPTRAB9ANPC1PKMLMNA | |
| SCHEMBL9221208 | 0.90 | NPC1 (0.81) | MAPTRAB9ANPC1PKMLMNA | |
| SCHEMBL1604280 | 0.88 | MAPT (0.79) | MAPTRAB9ANPC1PKMLMNA | |
| SCHEMBL31436352 | 0.88 | MAPT (0.79) | MAPTRAB9ANPC1PKMLMNA | |
| SCHEMBL9231011 | 0.87 | MAPT (0.77) | MAPTRAB9ANPC1PKMLMNA | |
| SCHEMBL6793181 | 0.87 | RAB9A (0.77) | MAPTRAB9ANPC1PKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060074108-A1 | Matrix metalloprotease (MMP) inhibitors and their application in cosmetic and pharmaceutical composition | BIODERM RESEARCH (US) | 2006-04-06 | — | — | US | claimed |
| JP-7126543-A | — | — | None | — | — | JP | disclosed |
| CN-117144701-A | Wear-resistant steel strand and preparation method thereof | 河北九天科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-109422677-B | Method for synthesizing chiral 3, 5-diaryl cyclohexenone pyridine nitrogen-oxygen compound | 中国科学技术大学 | 2020-08-28 | — | — | CN | disclosed |
| CN-109422677-A | A kind of method of synthesis of chiral 3,5- diaryl cyclonene pyridine nitrogen-oxygen compound | 中国科学技术大学 | 2019-03-05 | — | — | CN | disclosed |
| CN-104788370-A | Configuration-controllable method for synthesizing 2-(4-nitryl) butyryl pyridine nitrogen-oxygen compounds | USTC UNIV SCIENCE TECH CN | 2015-07-22 | — | — | CN | disclosed |
| US-7872029-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN J PHILLIP | 2011-01-18 | — | — | US | disclosed |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Robinson, Thomas Philip (US) | 2009-01-15 | — | — | US | disclosed |
| US-7432303-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Bowen, J. Phillip (US) | 2008-10-07 | — | — | US | disclosed |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2005-07-07 | — | — | US | disclosed |
| US-6462075-B1 | USE OF CHALCONE AND ITS DERIVATIVES AS ANTITUMOR/ANTICANCER AGENTS AND TO TREAT A NUMBER OF CONDITIONS OR DISEASE STATES IN WHICH ANGIOGENESIS IS A FACTOR INCLUDING PSORIASIS, ACNE, ROSACEA, WARTS, ECZEMA, HEMANGIOMAS AND LYMPHANGIOGENESIS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2002-10-08 | — | — | US | disclosed |
| EP-1242352-A2 | CHALCONE AND ITS ANALOGS AS AGENTS FOR THE INHIBITION OF ANGIOGENESIS AND RELATED DISEASE STATES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020040029-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN, J. PHILLIP | 2002-04-04 | — | — | US | disclosed |
| WO-2001046110-A2 | CHALCONE AND ITS ANALOGS AS AGENTS FOR THE INHIBITION OF ANGIOGENESIS AND RELATED DISEASE STATES | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| US-6248870-B1 | OLIGO-2,6-PYRIMIDINE COMPLEXING AGENT. | NYCOMED IMAGING AS (NO) | 2001-06-19 | — | — | US | disclosed |
| US-5817774-A | Unsymmetrical complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods | STERLING WINTHROP INCORPORATION (US) | 1998-10-06 | — | — | US | disclosed |
| US-5559214-A | Unsymmetrical complexing agents and targeting immunoreagents useful in thearpeutic and diagnostic compositions and methods | STERLING WINTHROP INC. (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0677293-A1 | PHARMACEUTICAL USE OF TERPYRIDINE DERIVATIVE | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1995-10-18 | — | — | EP | disclosed |
| JP-H07126543-A | INDOLIZINE COLOR AND METHOD FOR IMPROVING SOLUBILITY | TDK CORP | 1995-05-16 | — | — | JP | disclosed |
| US-3989708-A | HYPOTENSIVE, CORONARY VESSEL DILATORS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040029-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | MAPT 1111/4885RAB9A 2087/4885NPC1 1622/4885 |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | MAPT 1274/4885RAB9A 2188/4885NPC1 1709/4885 |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, VEGFA, FLT4 | MAPT 341/4885RAB9A 2231/4885NPC1 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.